
Oncternal Therapeutics Investor Relations Material
Latest events

Q2 2024
Oncternal Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Oncternal Therapeutics Inc
Access all reports
Oncternal Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing oncology therapies aimed at addressing cancers with critical unmet medical needs. Their diverse pipeline of treatments targets hematological malignancies and prostate cancer through multiple modalities. Their investigational product candidates include ONCT-808, an autologous CAR T cell therapy targeting ROR1 for patients with multiple hematologic and solid malignancies; ONCT-534, a Dual-Action Androgen Receptor Inhibitor (DAARI) for advanced prostate cancer; and Zilovertamab, a monoclonal antibody that inhibits the ROR1 protein expressed in various malignancies. The company is headquartered in San Diego, California, and its shares are listed on the Nasdaq.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
ONCT
Country
🇺🇸 United States